

CITATION REPORT

List of articles citing

Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

DOI: 10.1182/blood.v89.12.4531
Blood, 1997, 89, 4531-4536.

Source: <https://exaly.com/paper-pdf/28407130/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1047	Allogeneic bone marrow transplantation for hematological malignancies--controversies and recent advances. 1997 , 36, 549-64		41
1046	FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission. <i>Bone Marrow Transplantation</i> , 1998 , 22, 1137-43	4.4	17
1045	Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. 1998 , 41, 453-9		110
1044	[Current developments in hematology and internal medicine oncology]. 1998 , 39, 346-54		0
1043	Developments in allogeneic peripheral blood progenitor cell transplantation. 1998 , 103, 594-600		19
1042	Seasonal variation in the incidence of Hodgkin's disease. 1998 , 103, 653-62		16
1041	Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone. 1998 , 103, 565-7		19
1040	Developments in allogeneic peripheral blood progenitor cell transplantation. 1998 , 102, 594-600		2
1039	Crohn's disease remission with phenelzine treatment. 1998 , 115, 1034-5		32
1038	Hematopoietic stem cell transplantation in Crohn's disease. 1998 , 115, 1035-6		6
1037	Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. 1998 , 16, 2817-24		809
1036	Hematopoietic stem cell transplantation in chronic lymphocytic leukemia: a report of 12 patients from a single institution. 1998 , 9, 167-72		18
1035	Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoablation for the Treatment of Malignant and Nonmalignant Hematologic Diseases. <i>Blood</i> , 1998 , 91, 756-763	2.2	1780
1034	Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 1998 , 92, 1910-1917	2.2	129
1033	Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. 1999 , 10, 1293-9		109
1032	Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 1999 , 34, 185-90	1.9	46
1031	Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. 1999 , 17, 208-15		198

1030	Purine analog regimens for allogeneic transplant?. 1999 , 17, 1958-60		3
1029	Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. 1999 , 17, 1234		110
1028	Engraftment Kinetics After Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation: Full Donor T-Cell Chimerism Precedes Alloimmune Responses. <i>Blood</i> , 1999 , 94, 3234-3241		472
1027	The graft-versus-leukemia effects of allogeneic cell therapy. 1999 , 50, 369-86		104
1026	Graft-vs.-malignancy with allogeneic blood stem cell transplantation: a potential primary treatment modality. 1999 , 3 Suppl 1, 52-8		9
1025	Stem-cell transplant preparative regimens. 1999 , 3 Suppl 1, 23-34		4
1024	Intensive treatment for multiple myeloma: where do we stand?. 1999 , 106, 18-27		16
1023	Management of relapsed acute myeloid leukaemia. 1999 , 106, 851-9		34
1022	Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect. 1999 , 107, 396-400		33
1021	The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. 1999 , 107, 877-82		55
1020	Mini-allografts' for haematological malignancies: an alternative to conventional myeloablative marrow transplantation. 1999 , 29, 308-14		10
1019	Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1999 , 23, 145-50	4.4	19
1018	Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. <i>Bone Marrow Transplantation</i> , 1999 , 23, 107-10	4.4	43
1017	Epstein-Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999 , 23, 629-30	4.4	26
1016	Fludarabine-based preparative protocol for unrelated donor cord blood transplantation in children: successful engraftment with minimal toxicity. <i>Bone Marrow Transplantation</i> , 1999 , 23, 849-51	4.4	8
1015	Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. <i>Bone Marrow Transplantation</i> , 1999 , 23, 1055-60	4.4	221
1014	Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. <i>Bone Marrow Transplantation</i> , 1999 , 24, 735-9	4.4	31
1013	Use of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: induction of graft-vs.-malignancy as treatment for malignant diseases. 1999 , 14, 45-9		6

1012	Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. 1999 , 353, 1755-9	350
1011	Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. 1999 , 13, 1041-57, vii-viii	38
1010	Allogeneic transplantation of peripheral blood stem cells. 1999 , 12, 261-78	1
1009	Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi anemia. 1999 , 21, 237-9	43
1008	Hematopoietic stem cell transplantation in rheumatic diseases. 1999 , 11, 167-72	13
1007	New Developments in the Therapy of Acute Myelocytic Leukemia. 2000 , 69-89	17
1006	OKT-3-based reconditioning regimen for early graft failure in HLA-non-identical stem cell transplants. 2000 , 111, 668-73	29
1005	Hematopoietic stem-cell transplantation from an unrelated donor. 2000 , 35, 43-6, 49-52, 55; discussion 55-6	2
1004	Conditioning regimens for allogeneic stem cell transplants. 2000 , 7, 339-42	18
1003	Nonmyeloablative hematopoietic stem cell allografting. 2000 , 5, 366-371	2
1002	Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies. 2000 , 18, 141-153	21
1001	Nonmyeloablative HPC transplantation. 2000 , 40, 758-60	2
1000	Topoisomerase II inhibitor-related acute myeloid leukaemia. 2000 , 109, 13-23	148
999	Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Soci��t�� Fran��aise de Greffe de moelle (SFGM). 2000 , 108, 400-7	119
998	Incidence of mixed chimaerism and clinical outcome in 101 patients after myeloablative conditioning regimens and allogeneic stem cell transplantation. 2000 , 109, 743-50	21
997	New strategies for bone marrow transplantation. 2000 , 12, 542-51	38
996	Is it time to reduce toxicity by non-myeloablative conditioning for allogeneic stem cell transplantation in children?. 2000 , 4, 247-51	3
995	Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients. <i>Bone Marrow Transplantation</i> , 2000 , 26, 17-22	4.4 15

994	Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. <i>Bone Marrow Transplantation</i> , 2000 , 26, 1-16	4.4	34
993	Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. <i>Bone Marrow Transplantation</i> , 2000 , 26, 119-25	4.4	66
992	High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. <i>Bone Marrow Transplantation</i> , 2000 , 26, 251-5	4.4	93
991	Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2000 , 26, 243-50	4.4	56
990	Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. <i>Bone Marrow Transplantation</i> , 2000 , 26, 445-9	4.4	79
989	Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. <i>Bone Marrow Transplantation</i> , 2000 , 26, 615-20	4.4	67
988	Pure red cell aplasia after allogeneic stem cell transplantation with reduced conditioning. <i>Bone Marrow Transplantation</i> , 2000 , 26, 911-5	4.4	23
987	Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Soci�t� Fran�aise de Greffe de Moelle (SFGM). <i>Bone Marrow Transplantation</i> , 2000 , 26, 1157-63	4.4	124
986	Allogeneic stem cell transplantation in a patient with refractory Burkitt's lymphoma using non-myeloablative conditioning regimen. <i>Bone Marrow Transplantation</i> , 2000 , 26, 1351-4	4.4	14
985	Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases. <i>Bone Marrow Transplantation</i> , 2000 , 25, 131-3	4.4	49
984	The prophylactic potential of fludarabine monophosphate in graft-versus-host disease after bone marrow transplantation in murine models. <i>Bone Marrow Transplantation</i> , 2000 , 25, 263-6	4.4	8
983	Mini-allografts: ongoing trials in humans. <i>Bone Marrow Transplantation</i> , 2000 , 25, 345-50	4.4	181
982	Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. <i>Bone Marrow Transplantation</i> , 2000 , 25 Suppl 2, S54-7	4.4	11
981	Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. <i>Bone Marrow Transplantation</i> , 2000 , 25, 1021-8	4.4	148
980	Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. 2000 , 111, 18-29		1
979	Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. 2000 , 111, 292-302		4
978	Non-myeloablative stem cell transplants. 2000 , 111, 6-17		0
977	Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. 2000 , 111, 797-800		

976	Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. 2000 , 28, 853-7		99
975	Adoptive allogeneic immunotherapy--history and future perspectives. 2000 , 23, 133-50		16
974	Does hemopoietic stem cell transplantation have a role in treatment of severe rheumatoid arthritis?. 2000 , 20, 17-23		6
973	Tolerance induction for solid organ grafts with donor-derived hematopoietic reconstitution. 2000 , 22, 147-64		3
972	Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect. 2000 , 2, 132-9		19
971	Current trends in the management of chronic myelogenous leukemia. 2000 , 79, 345-54		35
970	Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. <i>Blood</i> , 2000 , 96, 1239-1246		128
969	Erratum in Ledru et al. Alteration of tumor necrosis factor β -cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. <i>Blood</i> . 2000;95:3191-3198.. <i>Blood</i> , 2000 , 96, 1673-1673	2.2	
968	In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. <i>Blood</i> , 2000 , 96, 2419-2425	2.2	445
967	How I treat older patients with AML. <i>Blood</i> , 2000 , 96, 1670-1673	2.2	101
966	Bone Marrow and Peripheral Blood Hematopoietic Stem Cell Transplantation: Focus on Autografting. 2000 , 46, 1239-1251		2
965	TRANSPLANTE DE MEDULA OSSEA: UMA REVISÃO HISTÓRICA. 2000 , 33, 209		3
964	Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. 2000 , 18, 947-55		172
963	High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. 2000 , 18, 527-36		155
962	Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. 2000 , 18, 3918-24		207
961	Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia. 2000 , 6, 141-7		9
960	Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. 2000 , 18, 3031-7		247
959	Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. 2000 , 5, 215-23		53

958	Correction of the hyper-IgM syndrome after liver and bone marrow transplantation. 2000 , 342, 320-4	90
957	Cancer immunotherapy with alloreactive lymphocytes. 2000 , 343, 802-3	23
956	Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations. 2000 , 5, 487-96	18
955	Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease. 2000 , 26, 411-27	6
954	Ex vivo expanded allogeneic cord blood progenitor cell transplantation with a non-myeloablative conditioning regimen would cure autoimmune diseases. 2000 , 54, 423-4	2
953	Haemopoietic stem-cell transplantation: recent progress and future promise. 2000 , 1, 227-34	40
952	Second allogeneic transplantation after failure of first autologous transplantation. 2000 , 6, 272-9	83
951	Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. 2000 , 6, 309-20	221
950	Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. 2000 , 343, 750-8	859
949	High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. 2000 , 1, 197-209; discussion 210	6
948	Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies. 2000 , 39, 5-26	54
947	Liver disease in primary immunodeficiencies. 2000 , 32, 9-10	7
946	Allogeneic transplantation using non-myeloablative transplant regimens. 2001 , 14, 701-22	12
945	Exploiting graft-versus-tumour responses using donor leukocyte infusions. 2001 , 14, 723-39	7
944	Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies. 2001 , 3, 253-60	5
943	In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. 2001 , 3, 197-201	43
942	Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. 2001 , 15, 97-120	21
941	Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation. 2001 , 7, 163-70	20

940	Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. 2001 , 7, 230-8		38
939	Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. 2001 , 7, 473-87		205
938	Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches. 2001 , 7, 656-64		29
937	Nucleoside analogues in the treatment of haematological malignancies. 2001 , 2, 929-43		51
936	Immunotherapy of cancer with alloreactive lymphocytes. 2001 , 2, 491-8		34
935	Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen. 2001 , 7, 352-8		33
934	Postremission therapy in adults with acute myeloid leukemia. 2001 , 38, 17-23		8
933	Extending the role of allogeneic stem-cell transplantation. 2001 , 357, 652-4		8
932	Pediatric hematopoietic stem cell transplantation. 2001 , 15, 795-808		14
931	Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. 2001 , 3, 203-10		20
930	[Hematopoietic allogeneic transplantation with attenuated conditioning regimen on an outpatient basis. First experience in Spain]. 2001 , 116, 580-2		2
929	Nonmyeloablative transplantation in children. Current status and future prospects. 2001 , 15, 809-34, vii-viii		10
928	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. <i>Blood</i> , 2001 , 97, 3390-400	2.2	1183
927	Features of the engraftment of allogeneic hematopoietic stem cells using reduced-intensity conditioning regimens. <i>Leukemia and Lymphoma</i> , 2001 , 42, 145-50	1.9	11
926	Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients. <i>Leukemia and Lymphoma</i> , 2001 , 42, 347-55	1.9	5
925	Non-myeloablative transplants for malignant disease. 2001 , 2001, 375-91		80
924	Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. 2001 , 19, 2134-41		72
923	Recombinant parvovirus B19 empty capsids inhibit fetal hematopoietic colony formation in vitro. 2001 , 16, 26-31		14

922	Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. 2001 , 19, 3340-9		78
921	Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. 2001 , 71, 880-5		32
920	Nonmyeloablative hematopoietic cell transplant for treatment of immune deficiency. 2001 , 13, 539-45		11
919	Reducing transplant toxicity. 2001 , 8, 342-8		10
918	Allogeneic stem cell transplantation for renal cell carcinoma. 2001 , 11, 495-502		11
917	Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. <i>Blood</i> , 2001 , 97, 63-72	2.2	245
916	Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T-cell antigen receptor-alpha-beta. <i>Blood</i> , 2001 , 97, 3458-65	2.2	19
915	Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. <i>Blood</i> , 2001 , 97, 631-7	2.2	508
914	Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene. <i>Blood</i> , 2001 , 97, 2506-13	2.2	24
913	High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. <i>Blood</i> , 2001 , 97, 2574-9	2.2	155
912	Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. <i>Blood</i> , 2001 , 98, 3456-64	2.2	242
911	Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. <i>Blood</i> , 2001 , 98, 3584-8	2.2	93
910	A decade of progress in allogeneic hematopoietic cell transplantation: 1990-2000. 2001 , 81, 1-59		1
909	Nonablative allogeneic hematopoietic stem cell transplantation. 2001 , 13, 27-32		9
908	Nonmyeloablative hematopoietic cell transplantation. 2001 , 13, 95-100		23
907	Cellular therapy: exploiting NK cell alloreactivity in transplantation. 2001 , 8, 355-9		64
906	Allogeneic transplantation of blood stem cells: coming of age?. 2001 , 80, 127-36		6
905	Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant. 2001 , 80, 521-4		7

904	A case of refractory idiopathic pure red cell aplasia responsive to fludarabine treatment. 2001 , 112, 527-9	2
903	Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia. 2001 , 112, 392-6	28
902	Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens. 2001 , 113, 446-54	26
901	Analysis of chimaerism in thalassaemic children undergoing stem cell transplantation. 2001 , 114, 219-25	17
900	Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant. 2001 , 115, 622-9	61
899	Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. 2001 , 115, 653-9	89
898	Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. 2001 , 115, 935-44	52
897	Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation. 2001 , 123, 162-9	8
896	Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two cases. 2001 , 23, 135-8	
895	Management of high-risk myelodysplastic syndromes. 2001 , 40, 215-28	6
894	Novel approaches to transplant conditioning. 2001 , 19, 43-57	1
893	Recent advances in the treatment of AML. 2001 , 19, 107-18	2
892	The role of purine analogue combinations in the management of acute leukemias. 2001 , 19, 151-7	8
891	Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. 2001 , 66, 241-4	63
890	Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. 2001 , 10, 419-25	70
889	Sclerosing cholangitis in the paediatric patient. 2001 , 15, 681-90	21
888	Bone marrow transplantation in a case of severe, type II congenital dyserythropoietic anaemia (CDA II). <i>Bone Marrow Transplantation</i> , 2001 , 27, 213-5	4-4 30
887	Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2001 , 27, 155-62	4-4 9

886	A fludarabine-based conditioning regimen for severe aplastic anemia. <i>Bone Marrow Transplantation</i> , 2001 , 27, 125-8	4.4	34
885	Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. <i>Bone Marrow Transplantation</i> , 2001 , 27 Suppl 2, S13-22	4.4	26
884	Unrelated cord blood transplantation in a Fanconi anemia patient using fludarabine-based conditioning. <i>Bone Marrow Transplantation</i> , 2001 , 28, 110-2	4.4	20
883	Acute left ventricular failure following melphalan and fludarabine conditioning. <i>Bone Marrow Transplantation</i> , 2001 , 28, 101-3	4.4	46
882	Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. <i>Bone Marrow Transplantation</i> , 2001 , 28, 243-9	4.4	69
881	Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001 , 28, 341-7	4.4	62
880	Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001 , 28, 491-5	4.4	27
879	Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2001 , 28, 557-62	4.4	33
878	Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions. <i>Bone Marrow Transplantation</i> , 2001 , 28, 545-9	4.4	58
877	A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2001 , 28, 643-7	4.4	42
876	Successful non-myeloablative stem cell transplantation for a heavily transfused woman with severe aplastic anemia complicated by heart failure. <i>Bone Marrow Transplantation</i> , 2001 , 28, 783-5	4.4	10
875	Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. 2001 , 15, 293-302		180
874	Immunotherapy by non-myeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation. 2001 , 15, 642-6		25
873	Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. 2001 , 15, 1841-7		77
872	Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations. 2001 , 15, 1967-75		39
871	Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders. 2001 , 5, 135-46		26
870	Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. 2001 , 29, 362-70		89
869	Acute graft-vs-host disease: pathobiology and management. 2001 , 29, 259-77		273

868	Acute Leukemias VIII. <i>Hamatologie Und Bluttransfusion</i> , 2001 ,			1
867	Bone marrow transplantation for CD40 ligand deficiency: a single centre experience. 2001 , 84, 508-11			35
866	Acute myeloid leukemia. 2001 , 2001, 62-86			90
865	Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "natural suppressor" cells. 2001 , 167, 2087-96			157
864	CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. 2001 , 98, 7492-7			86
863	Appropriate targets for monoclonal antibodies in the induction of transplantation tolerance. 2001 , 356, 659-63			5
862	Tolerance, mixed chimerism and protection against graft-versus-host disease after total lymphoid irradiation. 2001 , 356, 739-48			31
861	Novel approaches to allogeneic stem cell therapy. 2001 , 1, 3-15			9
860	Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients. <i>Bone Marrow Transplantation</i> , 2001 , 27, 999-1005	4.4		6
859	Engraftment syndrome following hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001 , 27, 893-8	4.4		286
858	The graft-versus-tumor potential of allogeneic cell therapy: an update on donor leukocyte infusions and nonmyeloablative allogeneic stem cell transplantation. 2001 , 10, 465-80			11
857	[Secondary medullary aplasia from accidental radiation:therapeutic options and evolution of the concept]. 2002 , 80, 694-9			1
856	Gene therapy-based treatment for HIV-positive patients with malignancies. 2002 , 11, 809-16			14
855	Nonmyeloablative allogeneic hematopoietic stem cell transplantation. 2002 , 11, 243-63			13
854	Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. 2002 , 11, 659-68			16
853	Viral abrogation of stem cell transplantation tolerance causes graft rejection and host death by different mechanisms. 2002 , 168, 6047-56			40
852	Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. <i>Blood</i> , 2002 , 99, 4618-25	2.2		276
851	Serial evaluation of the oncological pediatric risk of mortality (O-PRISM) score following allogeneic bone marrow transplantation in children. <i>Bone Marrow Transplantation</i> , 2002 , 29, 383-9	4.4		20

850	Follow up of hemopoietic chimerism in individuals given allogeneic hemopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen: a prospective study in a single institution. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1509-11	1.9	14
849	Treatment of lymphoid malignancies with non-myeloablative stem cell transplantation. 2002 , 7, 151-5		1
848	Recovery of lymphocyte and dendritic cell subsets following reduced intensity allogeneic bone marrow transplantation. 2002 , 7, 157-64		29
847	Successful reduced-intensity stem cell transplant from one-locus HLA-mismatched unrelated cord blood after rejection of unrelated bone marrow in an infant with myelogenous leukemia. 2002 , 7, 101-3		1
846	Is there an upper age limit for bone marrow transplantation?. <i>Bone Marrow Transplantation</i> , 2002 , 29, 277-84	4.4	33
845	Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin. <i>Bone Marrow Transplantation</i> , 2002 , 29, 237-41	4.4	20
844	Myelodysplastic syndromes. 2002 , 2002, 136-61		107
843	Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM). <i>Bone Marrow Transplantation</i> , 2002 , 29, 943-7	4.4	17
842	Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia. 2002 , 16, 581-6		18
841	Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin's disease. 2002 , 13 Suppl 1, 128-32		21
840	Successful treatment of Griscelli syndrome with unrelated donor allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002 , 29, 995-8	4.4	30
839	No cytomegalovirus-related deaths after non-ablative stem cell allografts. 2002 , 7, 95-9		9
838	Bone marrow transplantation for multiple myeloma: where we are today. 2002 , 14, 147-51		4
837	Nonmyeloablative hematopoietic transplantation for treatment of malignant diseases. 2002 , 7, 275-278		2
836	Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture?. 2002 , 15, 347-53		42
835	Reduced-intensity allogeneic transplantation for lymphoma. 2002 , 14, 475-83		2
834	Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. 2002 , 8, 2-11		28
833	Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. <i>Blood</i> , 2002 , 100, 442-50	2.2	42

832	Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. <i>Blood</i> , 2002 , 99, 75-82	2.2	133
831	High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. <i>Blood</i> , 2002 , 99, 4357-63	2.2	324
830	Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. <i>Blood</i> , 2002 , 99, 698-701	2.2	82
829	Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. <i>Blood</i> , 2002 , 99, 1978-85	2.2	197
828	Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. <i>Blood</i> , 2002 , 99, 2586-91	2.2	131
827	Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2002 , 99, 2255-8	2.2	131
826	Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. <i>Blood</i> , 2002 , 100, 4310-6	2.2	344
825	Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. <i>Blood</i> , 2002 , 100, 755-60	2.2	209
824	Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. <i>Blood</i> , 2002 , 100, 2243-5	2.2	152
823	Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants. <i>Blood</i> , 2002 , 100, 1894-902	2.2	47
822	Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. <i>Blood</i> , 2002 , 100, 3121-7	2.2	215
821	Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. <i>Blood</i> , 2002 , 100, 3919-24	2.2	160
820	Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2002 , 29 Suppl 1, S1-4	4.4	8
819	Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. 2002 , 73, 1386-91		166
818	Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. 2002 , 346, 738-46		673
817	Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. 2002 , 8, 377-86		335
816	Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. 2002 , 11, 265-76		42
815	Myelodysplastic Syndrome. 2002 , 1, 301-311		1

814 Chronic Lymphocytic Leukemia. **2002**, 1, 127-143

813 Autologous and allogeneic transplantation for aggressive NHL. **2002**, 4, 223-40

12

812 Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity. **2002**, 8, 608-18

25

811 Umbilical cord blood transplantation: where do we stand?. **2002**, 8, 637-47

21

810 Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene. *Leukemia and Lymphoma*, **2002**, 43, 2011-6

1.9 11

809 Clinical developments in reduced intensity haematopoietic stem cell transplantation. **2002**, 2, 703-14

3

808 Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. *Leukemia and Lymphoma*, **2002**, 43, 1409-14

1.9 16

807 Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. **2002**, 8, 139-44

30

806 Phase II study of a moderate-intensity preparative regimen with allogeneic peripheral blood stem cell transplantation for hematologic diseases: the Texas Transplant Consortium experience. **2002**, 8, 420-8

10

805 Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. **2002**, 8, 512-20

206

804 Nonmyeloablative stem cell transplantation for solid tumors: expanding the application of allogeneic immunotherapy. **2002**, 39, 63-71

24

803 Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes. **2002**, 39, 57-62

17

802 Non-myeloablative stem cell transplantation for the treatment of cancer and life-threatening non-malignant disorders; past accomplishments and future goals. **2002**, 27, 159-66

8

801 High dose immunosuppressive therapy and stem cell transplantation in autoimmune and inflammatory diseases. **2002**, 2, 399-414

5

800 [Allogeneic stem cell transplantation after non-myeloablative conditioning regimen (mini-allogeneic stem cell transplantation)]. **2002**, 50, 42-4

799 Allogeneic Non-Myeloablative Peripheral-Blood Stem Cell Transplant in Solid Tumors. **2002**, 1, S32-S33

3

798 . **2002**,

5

797 The identification of renal cell carcinoma as a target for allogeneic based cancer immunotherapy. **2002**, 10, 227-34

8

796	Focus on acute leukemias. 2002 , 1, 417-20	138
795	Kinetics of stem cell engraftment and clearance of leukaemia cells after allogeneic stem cell transplantation with reduced intensity conditioning in chronic myeloid leukaemia. 2002 , 69, 7-10	8
794	Allogeneic stem cell transplantation for multiple myeloma. 2002 , 6, 205-24	12
793	Mini-allogeneic stem cell transplantation. 2002 , 10, 170-2	
792	Calendar of Events. 2002 , 10, 172-172	
791	Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. 2002 , 30, 89-96	26
790	Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning. 2002 , 30, 1346-53	24
789	Sustained molecular remission in a patient with CML in blastic crisis receiving dose-reduced hematopoietic stem-cell transplantation followed by early withdrawal of cyclosporine and prophylactic use of interferon-alpha. 2002 , 71, 196-9	3
788	Bone Marrow Transplantation for Immune Therapy. 2002 , 299-310	
787	Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. 2002 , 94, 2409-15	99
786	Allogeneic immunotherapy for relapsed multiple myeloma: Role of matched unrelated donors. 2002 , 1, 72-74	
785	Second allogeneic hematopoietic stem cell transplantation for leukemia relapse after first allogeneic transplantation: outcome of 16 patients in a single institution. 2002 , 75, 318-23	16
784	Long-term follow-up of allogeneic bone marrow transplantation after reduced-intensity conditioning in patients with chronic myelogenous leukemia in the chronic phase. 2002 , 75, 493-8	12
783	The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002). 2002 , 76 Suppl 2, 228-38	27
782	Non-myeloablative hematopoietic cell transplant for treatment of nonmalignant disorders in children. 2002 , 76 Suppl 2, 271-7	11
781	Maternal-fetal relationship, natural chimerism and bilateral transplantation tolerance as the basis for non-myeloablative stem cell transplantation. 2002 , 76 Suppl 1, 172-5	6
780	Update on non-myeloablative stem cell transplantation for hematologic malignancies. 2002 , 76 Suppl 1, 176-83	6
779	Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: results of the Mexican approach. 2002 , 76 Suppl 1, 376-9	27

778	The simplification of the SCT procedures in developing countries has resulted in cost-lowering and availability to more patients. 2002 , 76 Suppl 1, 380-2		33
777	Long-term outcome after allogeneic bone marrow transplantation for hematological malignancies with non-remission status. Results of a single-center study of 24 patients. 2002 , 81, 582-7		7
776	High-dose therapy for indolent lymphoma. 2002 , 41, 225-39		10
775	Critical review on non-myeloablative stem cell transplantation (NST). 2002 , 44, 175-90		11
774	Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). 2002 , 118, 67-73		82
773	Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. 2002 , 119, 144-54		67
772	Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. <i>Bone Marrow Transplantation</i> , 2002 , 30, 95-102	4.4	62
771	Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2002 , 30, 367-73	4.4	107
770	Partially matched related donor peripheral blood progenitor cell transplantation in paediatric patients adding fludarabine and anti-lymphocyte gamma-globulin. <i>Bone Marrow Transplantation</i> , 2002 , 30, 359-66	4.4	29
769	High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002 , 30, 267-71	4.4	19
768	Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience. <i>Bone Marrow Transplantation</i> , 2002 , 30, 651-9	4.4	12
767	Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?. <i>Bone Marrow Transplantation</i> , 2002 , 30, 797-804	4.4	31
766	Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma. <i>Bone Marrow Transplantation</i> , 2002 , 30, 805-12	4.4	1
765	Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. 2002 , 16, 1423-31		94
764	Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. 2002 , 16, 2423-8		84
763	History of haematopoietic stem-cell transplantation. 2002 , 2, 231-8		88
762	Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation. 2002 , 22, 64-9		13
761	Alemtuzumab in stem cell transplantation. 2002 , 19 Suppl, S33-47		20

760	Therapeutic applications of non-myeloablative hematopoietic stem cell transplantation in malignant disease. 2003 , 28, 1-11	6
759	Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies. 2003 , 82, 1-13	13
758	Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation. 2003 , 77, 3-14	25
757	Current status of therapeutic approaches to adult T-cell leukemia. 2003 , 78, 304-11	22
756	Graft-versus-host disease, the graft-versus-leukemia effect, and mixed chimerism following nonmyeloablative stem cell transplantation. 2003 , 78, 195-207	13
755	The Mexican approach to conduct nonmyeloablative stem cell transplantation should not be overlooked. 2003 , 77, 526-7	7
754	Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. 2003 , 82, 336-42	88
753	Allogeneic hematopoietic stem cell transplantation--yesterday, today, and tomorrow. 2003 , 31, 1-10	91
752	Nonmyeloablative therapy and allogeneic hematopoietic stem cell transplantation. 2003 , 31, 559-66	7
751	Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen. 2003 , 31, 873-80	17
750	Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. 2003 , 31, 865-72	38
749	Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. 2003 , 31, 924-33	22
748	Low-dose total-body irradiation and fludarabine followed by hematopoietic cell transplantation from HLA-identical sibling donors do not induce complete T-cell donor engraftment in most patients with progressive hematologic diseases. 2003 , 31, 934-40	4
747	Non-myeloablative bone marrow transplantation. 2003 , 34, 554-7	4
746	Hematopoietic cell transplantation: five decades of progress. 2003 , 34, 528-44	44
745	Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin's disease following autologous stem cell transplantation. 2003 , 34, 242-5	7
744	Development and application of quantitative real time PCR and RT-PCR assays that discriminate between the full-length and truncated herpes simplex virus thymidine kinase gene. 2003 , 109, 177-86	4
743	Reduced-intensity allogeneic hematopoietic cell transplantation: Graft versus tumor effects with decreased toxicity. 2003 , 7, 168-78	5

742	The expanding applications of non-myeloablative stem cell transplantation. 2003 , 7 Suppl 3, 95-100		9
741	Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. 2003 , 5, 132-9		26
740	Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies. 2003 , 25, 383-91		3
739	Novel treatment for refractory acute myeloid leukemia. 2003 , 7, 422-5		
738	A clinical role for peripheral blood lymphocyte infusions and perspectives on collection. 2003 , 7, 305-11		4
737	ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. 2003 , 43, 1153-61		62
736	Therapeutic challenges in childhood sickle cell disease. Part 1: current and future treatment options. 2003 , 120, 725-36		27
735	Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. 2003 , 121, 296-303		15
734	HLA-DRB1*16-restricted recognition of myeloid cells, including CD34+ CML progenitor cells. 2003 , 121, 721-9		4
733	Early reconstitution of the T-cell repertoire after non-myeloablative peripheral blood stem cell transplantation is from post-thymic T-cell expansion and is unaffected by graft-versus-host disease or mixed chimaerism. 2003 , 122, 934-43		38
732	Phenotype, function and chimaerism of monocyte-derived blood dendritic cells after allogeneic hematopoietic stem cell transplantation. 2003 , 123, 119-26		17
731	T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. 2003 , 123, 300-02		38
730	Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. 2003 , 123, 662-70		28
729	Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged ≥ 50 years compared to younger adults with low-risk disease. <i>Bone Marrow Transplantation</i> , 2003 , 31, 87-93	4.4	11
728	Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. <i>Bone Marrow Transplantation</i> , 2003 , 31, 253-61	4.4	120
727	Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis. <i>Bone Marrow Transplantation</i> , 2003 , 31, 305-8	4.4	8
726	Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. <i>Bone Marrow Transplantation</i> , 2003 , 31, 387-92	4.4	64
725	'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning. <i>Bone Marrow Transplantation</i> , 2003 , 31, 739-46	4.4	30

724	Successful T-cell-depleted, related haploidentical peripheral blood stem cell transplantation in a patient with Fanconi anaemia using a fludarabine-based preparative regimen without radiation. <i>Bone Marrow Transplantation</i> , 2003 , 31, 437-40	4.4	16
723	Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita. <i>Bone Marrow Transplantation</i> , 2003 , 31, 847-50	4.4	53
722	Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen. <i>Bone Marrow Transplantation</i> , 2003 , 31, 981-6	4.4	17
721	Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. <i>Bone Marrow Transplantation</i> , 2003 , 31, 1089-95	4.4	119
720	T-cell depletion does not necessarily compromise donor stem cell engraftment in patients receiving reduced-intensity conditioning regimens. <i>Bone Marrow Transplantation</i> , 2003 , 31, 1177; author reply 1179	4.4	1
719	Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2003 , 32, 125-9	4.4	33
718	A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2003 , 32, 557-61	4.4	5
717	Allogeneic stem cell transplantation with reduced-intensity conditioning is potentially feasible as an outpatient procedure. <i>Bone Marrow Transplantation</i> , 2003 , 32, 869-72	4.4	16
716	Late hemorrhagic cystitis after reduced-intensity hematopoietic stem cell transplantation (RIST). <i>Bone Marrow Transplantation</i> , 2003 , 32, 1089-95	4.4	25
715	Donor leukocyte infusions in acute myelogenous leukemia. 2003 , 17, 1035-7		9
714	Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. 2003 , 17, 2168-77		103
713	Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes. 2003 , 17, 1243-60		3
712	Recent advances in stem cell transplantation. Abstracts from the 11th International Symposium. Del Mar, California, USA. May 8-10, 2003. 2003 , 5, 561-80		
711	Allogeneic stem cell transplantation as immunotherapy for renal cell carcinoma: from immune enhancement to immune replacement. 2003 , 30, 611-22		8
710	Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. 2003 , 70, 1-10		25
709	Nonmyeloablative allogeneic hematopoietic stem cell transplantation for metastatic breast cancer. 2003 , 4, 39-45		5
708	Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. 2003 , 9, 266-72		26
707	Non-myeloablative allogeneic stem cell transplantation for metastatic renal cell carcinoma. 2003 , 21, 79-81		1

706	Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. 2003 , 9, 312-9		30
705	Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. 2003 , 9, 320-9		126
704	Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants. 2003 , 9, 373-82		54
703	Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. 2003 , 9, 355-63		119
702	Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. 2003 , 9, 472-81		68
701	Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. 2003 , 9, 519-28		230
700	Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed. 2003 , 9, 649-56		21
699	Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. 2003 , 9, 157-161		43
698	Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. 2003 , 9, 162-169		37
697	Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. 2003 , 9, 189-197		37
696	Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. <i>Blood</i> , 2003 , 102, 3052-9	2.2	153
695	Epidemiology and clinical burden of acute myeloid leukemia. 2003 , 3, 695-710		23
694	Purine nucleoside analogues in the treatment of myeloid leukemias. <i>Leukemia and Lymphoma</i> , 2003 , 44, 391-409	1.9	64
693	High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. 2003 , 36, 9-15		76
692	Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. <i>Blood</i> , 2003 , 102, 756-62	2.2	488
691	Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. 2003 , 21, 3060-5		55
690	The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML. 2003 , 3, 311-29		22
689	Transplantation in Hematology and Oncology II. 2003 ,		

688 Kidney Cancer. **2003**,

687	Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. 2003 , 21, 1480-4		148
686	Minitransplants: allogeneic stem cell transplantation with reduced toxicity. 2003 , 58, 37-45		1
685	Non-myeloablative hematopoietic stem cell transplantation for the treatment of adult T-cell lymphoma in a patient with advanced hepatic impairment. <i>Leukemia and Lymphoma</i> , 2003 , 44, 703-8	1.9	7
684	Current challenges in therapy of myelodysplastic syndromes. 2003 , 10, 60-7		4
683	Update on nonmyeloablative stem cell transplantation for hematologic malignancies. 2003 , 8, 118-124		1
682	Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy. 2003 , 26, 257-69		6
681	Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism. 2003 , 76, 297-305		58
680	Myelodysplastic syndrome. 2003 , 2003, 176-99		37
679	Hematopoietic stem-cell transplantation for the Bernard-Soulier syndrome. 2003 , 138, 79		26
678	Hematopoietic cell transplantation for benign hematological disorders and solid tumors. 2003 , 2003, 372-97		45
677	Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. <i>Blood</i> , 2003 , 101, 441-5	2.2	185
676	Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. <i>Blood</i> , 2003 , 101, 469-72	2.2	42
675	Transient expansion of Mac1+Ly6-G+Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions. <i>Blood</i> , 2003 , 102, 740-8	2.2	59
674	Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. <i>Blood</i> , 2003 , 102, 404-6	2.2	164
673	Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. <i>Blood</i> , 2003 , 102, 1915-9	2.2	369
672	Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. <i>Blood</i> , 2003 , 102, 820-6	2.2	172
671	Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. <i>Blood</i> , 2003 , 102, 470-6	2.2	169

670	Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. <i>Blood</i> , 2003 , 102, 827-33	2.2	390
669	Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. <i>Blood</i> , 2003 , 102, 3829-36	2.2	125
668	Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2003 , 102, 2777-85 ^{2.2}		216
667	Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma. <i>Blood</i> , 2003 , 102, 2300-7	2.2	78
666	Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose. <i>Blood</i> , 2003 , 102, 1943-50	2.2	42
665	Contamination of the blood supply in the 1980s and 1990s. 2003 , 138, 78-9		
664	Survival in Academy Award-winning actors and actresses. 2003 , 138, 77-8; author reply 77-8		1
663	Alcohol and congestive heart failure. 2003 , 138, 75-6; author reply 75-6		
662	Resident stress. 2003 , 138, W13-4		
661	Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review. 2003 , 10, 17-41		23
660	Nonmyeloablative allogeneic stem cell transplantation using alternative donors. 2004 , 11, 86-96		14
659	The risk of cytomegalovirus infection in non-myeloablative peripheral stem cell transplantation compared with conventional bone marrow transplantation. 2004 , 19, 172-6		4
658	Purine analogs in leukemia. 2004 , 51, 107-25		7
657	Hematopoietic Growth Factors in Oncology. 2004 ,		
656	Allogeneic peripheral blood stem cell transplantation using reduced intensity versus myeloablative conditioning regimens for the treatment of leukemia. 2004 , 13, 571-9		8
655	Adoptive Immunotherapy: Methods and Protocols. 2004 ,		
654	Graft-versus-host disease in mini-transplant. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1969-80	1.9	10
653	Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma. 2004 , 10, 6353S-9S		16

652	Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. 2004 , 10, 3586-92		125
651	Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning. 2004 , 112, 93-104		12
650	Conditioning regimens including high-dose busulfan cause a high incidence of transplant-related mortality after myeloablative stem cell transplantation. 2004 , 50, 178-83		1
649	Vesicles as initial skin manifestation of disseminated fusariosis after non-myeloablative stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2004 , 45, 631-3	1.9	9
648	Nonmyeloablative allogeneic immunotherapy for solid tumors. 2004 , 55, 459-75		25
647	Strategies to improve the outcome of stem cell transplantation in multiple myeloma. 2004 , 5, 9-23		11
646	Future prospects for fludarabine-containing regimens in the treatment of hematological cancers. 2004 , 5 Suppl 1, S76-86		3
645	Treatment of hematological malignancies with allogeneic nonmyeloablative stem cell transplantation: conditioning regimens with fludarabine. 2004 , 5 Suppl 1, S68-75		9
644	Reduced intensity transplantation: where are we now?. 2004 , 5 Suppl 3, S34-8		3
643	Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD. 2004 , 5, 395-402		6
642	Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation. 2004 , 5, 24-31		4
641	Non-myeloablative allogeneic transplantation -- state-of-the-art. 2004 , 8 Suppl 5, 12-8		6
640	New insights into haematopoietic stem cell transplantation for patients with haemoglobinopathies. 2004 , 125, 3-11		12
639	Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. 2004 , 124, 777-86		71
638	Non-myeloablative stem cell transplantation for severe combined immunodeficiency--Omenn syndrome. 2004 , 125, 406-7		13
637	Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. 2004 , 126, 837-43		16
636	Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level. 2004 , 44, 501-8		17
635	Pharmacokinetics of high-dose chemotherapy. <i>Bone Marrow Transplantation</i> , 2004 , 33, 259-69	4.4	34

634	Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial. <i>Bone Marrow Transplantation</i> , 2004 , 33, 477-82	4.4	37
633	A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2004 , 33, 881-9	4.4	58
632	Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. <i>Bone Marrow Transplantation</i> , 2004 , 33, 891-900	4.4	23
631	Allogeneic myeloablative transplantation for patients aged 50 years and over. <i>Bone Marrow Transplantation</i> , 2004 , 34, 29-35	4.4	28
630	Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004 , 34, 77-84	4.4	62
629	Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients. <i>Bone Marrow Transplantation</i> , 2004 , 34, 155-9	4.4	27
628	Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. <i>Bone Marrow Transplantation</i> , 2004 , 34, 309-16	4.4	23
627	Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004 , 34, 527-30	4.4	33
626	Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. <i>Bone Marrow Transplantation</i> , 2004 , 34, 721-7	4.4	171
625	Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. <i>Bone Marrow Transplantation</i> , 2004 , 34, 1083-8	4.4	37
624	Regimen-related toxicity following reduced-intensity stem-cell transplantation (RIST): comparison between Seattle criteria and National Cancer Center Common Toxicity Criteria (NCI-CTC) version 2.0. <i>Bone Marrow Transplantation</i> , 2004 , 34, 787-94	4.4	12
623	Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. <i>Bone Marrow Transplantation</i> , 2004 , 34, 1039-45	4.4	6
622	Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia. 2004 , 18, 1907-9		15
621	Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan. 2004 , 72, 448-50		6
620	Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease: indications and results. 2004 , 31, 27-32		22
619	Nonmyeloablative reduced-intensity transplantation in multiple myeloma. 2004 , 31, 33-6		6
618	Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. 2004 , 31, 37-46		17
617	Allogeneic stem cell transplantation as immunotherapy for nonhematological cancers. 2004 , 31, 47-55		19

616	The role of monoclonal antibodies in stem cell transplantation. 2004 , 31, 83-9	5
615	Update on myelodysplastic syndromes: new approaches to classification and therapy. 2004 , 31, 72-9	6
614	Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. 2004 , 32, 599-606	29
613	Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning. 2004 , 32, 1110-7	13
612	Unrelated donor marrow transplantation for congenital immunodeficiency and metabolic disease: an update of the experience of the Japan Marrow Donor Program. 2004 , 80, 174-82	7
611	Reduced-intensity hematopoietic stem cell transplantation for a patient with myelodysplastic syndrome and chronic obstructive pulmonary disease. 2004 , 80, 470-1	
610	Allogeneic stem cell transplantation for the treatment of advanced solid tumors. 2004 , 26, 95-108	17
609	Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. 2004 , 26, 71-94	60
608	Transplantation of hematopoietic stem cells for induction of unresponsiveness to organ allografts. 2004 , 26, 169-85	3
607	The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease. 2004 , 75, 200-4	5
606	Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation. 2004 , 76, 1-7	28
605	Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. 2004 , 51, 171-89	18
604	Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. 2004 , 22, 1136-51	254
603	Breaking dogmata to help patients: non-myeloablative haematopoietic stem cell transplantation. 2004 , 4, 1693-9	12
602	Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute myelogenous leukemia eligible for conventional allografting: a prospective study. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1191-5	1.9 19
601	Factors affecting engraftment of allogeneic hematopoietic stem cells after reduced-intensity conditioning. 2004 , 6, 589-2	9
600	Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. 2004 , 18, 703-13, xi	8
599	Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience. 2004 , 6, 172-81	15

598	Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures. 2004 , 223, 59-64		14
597	Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma. 2004 , 5 Suppl 1, S27-32		10
596	Unmanipulated reduced-intensity stem cell transplantation from a haploidentical donor mismatched at 3 HLA antigens to a patient with leukemic transformation of myelodysplastic syndrome: successful second transplantation after graft rejection. 2004 , 80, 449-52		3
595	Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. <i>Blood</i> , 2004 , 104, 1616-23	2.2	179
594	Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. 2004 , 10, 65-72		16
593	Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens. 2004 , 10, 1-22		54
592	Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. 2004 , 10, 178-85		169
591	Early central nervous system complications after reduced-intensity stem cell transplantation. 2004 , 10, 561-8		45
590	Incidence of invasive aspergillosis after allogeneic hematopoietic stem cell transplantation with a reduced-intensity regimen compared with transplantation with a conventional regimen. 2004 , 10, 645-52		33
589	Depletion of alloantigen-primed lymphocytes overcomes resistance to allogeneic bone marrow in mildly conditioned recipients. 2004 , 33, 238-47		2
588	Allogeneic stem-cell transplantation for renal-cell cancer. 2004 , 5, 561-7		8
587	Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. 2004 , 364, 156-62		129
586	Smarter rather than stronger treatment of haematological malignancies and non-malignant indications for stem-cell transplantation. 2004 , 364, 122-4		13
585	Scientific freedom and research cloning: can a ban be justified?. 2004 , 364, 124-6		5
584	Allogeneic Hematopoietic Cell Transplantation: A Historical Perspective. 2004 , 31, 21-32		4
583	A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. 2004 , 78, 1014-20		54
582	Reduced-intensity allogeneic hematopoietic stem-cell transplantation as an immunotherapy for metastatic colorectal cancer. 2004 , 78, 1740-6		11
581	Hematopoietic stem cell transplantation: a primer for the primary care physician. 2004 , 170, 1569-77		22

580	Reduced intensity versus truly nonmyeloablative conditioning for stem-cell transplant recipients. 2004 , 78, 964-5		6
579	Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. 2004 , 10, 1-7		53
578	Editorial Overview: Reduced-intensity allogeneic hematopoietic cell transplantation: shifting paradigms, new definitions, new challenges. 2004 , 9, 36-38		
577	Transplant strategies for myelodysplastic syndrome. 2004 , 17, 559-572		1
576	Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. <i>Blood</i> , 2004 , 103, 78-84	2.2	129
575	Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2004 , 104, 865-72	2.2	320
574	Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2004 , 103, 725-31	2.2	111
573	Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors. <i>Blood</i> , 2004 , 103, 1560-3	2.2	47
572	BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. <i>Blood</i> , 2004 , 103, 428-34	2.2	160
571	Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. <i>Blood</i> , 2004 , 103, 435-41	2.2	111
570	Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Blood</i> , 2004 , 104, 2254-62	2.2	210
569	Successful allogeneic bone marrow transplantation for acute myelogenous leukemia after drug-induced cardiomyopathy. 2004 , 204, 85-91		8
568	Stem cell transplantation: graft-mediated antileukemia effects. 2005 , 109, 421-44		5
567	Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease. 2005 , 12, 45-54		27
566	Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. 2005 , 79, 821-7		24
565	Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions. 2005 , 28, 281-8		33
564	Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. 2005 , 12, 435-43		31
563	Cellular adoptive immunotherapy after allogeneic stem cell transplantation. 2005 , 17, 617-21		20

562	Current update on reduced intensity regimens for allogeneic stem cell transplantation. 2005 , 10 Suppl 1, 64-5		1
561	Chronic graft-versus-host disease after reduced-intensity stem cell transplantation versus conventional hematopoietic stem cell transplantation. 2005 , 10, 1-10		5
560	Allogeneic transplantation for chronic myelogenous leukemia. 2005 , 10 Suppl 1, 15-8		0
559	Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. <i>Blood</i> , 2005 , 105, 3035-41	2.2	36
558	Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. <i>Blood</i> , 2005 , 105, 1810-4	2.2	247
557	Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. <i>Blood</i> , 2005 , 105, 4532-9	2.2	206
556	Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. <i>Blood</i> , 2005 , 106, 2969-76	2.2	142
555	Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Blood</i> , 2005 , 106, 3314-21	2.2	58
554	Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. <i>Blood</i> , 2005 , 106, 4407-11	2.2	65
553	Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. <i>Blood</i> , 2005 , 105, 879-85	2.2	180
552	Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. 2005 , 19, 153-64		64
551	Extramedullary leukemic relapses following hematopoietic stem cell transplantation with nonmyeloablative conditioning. 2005 , 82, 262-5		12
550	The influence of human platelet antigen match on the success of allogeneic peripheral blood progenitor cell transplantation following a reduced-intensity conditioning regimen. 2005 , 45, 195-201		6
549	The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation. 2005 , 45, 1382-90		42
548	Reduced intensity transplants (RIT) in pediatrics: a review. 2005 , 9 Suppl 7, 63-70		9
547	Biology and management of relapsed acute myeloid leukaemia. 2005 , 129, 18-34		72
546	Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. 2005 , 129, 381-91		38
545	Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors. 2005 , 129, 795-802		14

544	Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. 2005 , 130, 256-64		29
543	Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. 2005 , 130, 394-403		95
542	Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. 2005 , 130, 561-7		112
541	188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. 2005 , 130, 604-13		84
540	Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. <i>Bone Marrow Transplantation</i> , 2005 , 35, 277-82	4.4	39
539	Significance of one human leukocyte antigen mismatch on outcome of nonmyeloablative allogeneic stem cell transplantation from related donors using the Mexican schedule. <i>Bone Marrow Transplantation</i> , 2005 , 35, 335-9	4.4	2
538	A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. <i>Bone Marrow Transplantation</i> , 2005 , 35, 557-66	4.4	25
537	The hope and the reality of reduced intensity transplants in children with malignant diseases. <i>Bone Marrow Transplantation</i> , 2005 , 35 Suppl 1, S39-43	4.4	5
536	Outcome of unrelated transplants in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2005 , 35, 675-81	4.4	21
535	Optimal initial dose of oral cyclosporine in relation to its toxicities for graft-versus-host disease prophylaxis following reduced-intensity stem cell transplantation in Japanese patients. <i>Bone Marrow Transplantation</i> , 2005 , 35, 1079-82	4.4	5
534	CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. <i>Bone Marrow Transplantation</i> , 2005 , 35, 1127-32	4.4	15
533	Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 2005 , 36, 157-62	4.4	52
532	Successful HSCT using nonradiotherapy-based conditioning regimens and alternative donors in patients with Fanconi anaemia--experience in a single UK centre. <i>Bone Marrow Transplantation</i> , 2005 , 36, 405-10	4.4	37
531	Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'. <i>Bone Marrow Transplantation</i> , 2005 , 36, 565-74	4.4	17
530	Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study. <i>Bone Marrow Transplantation</i> , 2005 , 36, 443-51	4.4	11
529	Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts. <i>Bone Marrow Transplantation</i> , 2005 , 36, 675-82	4.4	16
528	Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years. <i>Bone Marrow Transplantation</i> , 2005 , 36, 667-74	4.4	23
527	Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. <i>Bone Marrow Transplantation</i> , 2005 , 36, 683-9	4.4	41

526	Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2005 , 36, 901-6	4-4	12
525	The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. <i>Bone Marrow Transplantation</i> , 2005 , 36, 1042-7	4-4	31
524	Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. 2005 , 19, 7-12		77
523	Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. 2005 , 19, 990-7		52
522	The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. 2005 , 19, 916-20		92
521	Allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia in first complete remission: new answers for an old question. 2005 , 19, 891-3		14
520	Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). 2005 , 19, 1013-7		380
519	Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. 2005 , 113, 813-30		55
518	Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. 2005 , 74, 144-51		65
517	Advances in the diagnosis and treatment of chronic lymphocytic leukemia. 2005 , 23, 34-40		4
516	Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and 2005, 84, 331-8		6
515	Chronic myeloid leukemia: a model for oncology. 2005 , 84, 487-97		43
514	Nonmyeloablative allogeneic stem cell transplantation in metastatic renal cell carcinoma: a new therapeutic option or just a clinical experiment?. 2005 , 23, 213-20		3
513	Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care. 2005 , 131, 1-13		28
512	Bone marrow transplantation for sickle cell anemia: progress and prospects. 2005 , 44, 436-40		21
511	Reduced intensity hematopoietic stem-cell transplantation across human leukocyte antigen barriers in a patient with congenital amegakaryocytic thrombocytopenia and monosomy 7. 2005 , 45, 212-6		19
510	Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning. 2005 , 145-175		
509	Stem Cell Transplantation. 2005 ,		

508	Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). 2005 , 11, 7757-63		113
507	Mechanisms of the antitumor responses and host-versus-graft reactions induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: a critical role for recipient CD4+ T cells and recipient leukocyte infusion-derived IFN-gamma-producing CD8+ T cells. 2005 , 175, 665-76		54
506	Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. 2005 , 23, 1993-2003		277
505	Interleukin-1 polymorphisms and graft-vs-host disease. <i>Leukemia and Lymphoma</i> , 2005 , 46, 517-23	1.9	14
504	Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. <i>Blood</i> , 2005 , 106, 4381-8	2.2	67
503	Dendritic cells in allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2005 , 46, 1387-96	1.9	13
502	Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. 2005 , 23, 6690-8		53
501	The Mexican approach to conduct allogeneic stem cell transplantation: braking dogmata and facing the Matthew effect. 2005 , 10 Suppl 1, 154-60		6
500	Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years?. 2005 , 2005, 384-9		26
499	Non-myeloablative allogeneic haemopoietic stem-cell transplantation for treatment of metastatic invasive thymoma. 2005 , 6, 626-8		4
498	Sustained molecular remission by non-myeloablative stem cell transplantation after autologous hematopoietic stem cell transplantation in a patient with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2005 , 46, 1217-22	1.9	1
497	Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma. 2005 , 11, 593-9		25
496	Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. 2005 , 11, 764-72		61
495	Intraosseus transplantation of donor-derived hematopoietic stem and progenitor cells induces donor-specific chimerism and extends composite tissue allograft survival. 2005 , 37, 2303-8		35
494	Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. 2005 , 14, 207-19		34
493	[Immunotherapy with allogeneic haematopoietic stem cell transplantation: current status and perspectives]. 2005 , 26, 33-40		0
492	Allogeneic graft-versus-tumor effects: Mechanistic insights and therapeutic promise. 2005 , 2, 205-212		
491	Recent advances in chronic lymphocytic leukemia. 2006 , 24, 302-9		5

490	Donor cell leukemia after non-myeloablative allogeneic stem cell transplantation: a single institution experience. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1952-5	1.9	20
489	Allogeneic stem cell transplantation for patients with metastatic renal cell carcinoma. 2006 , 6, 1449-58		2
488	The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation. 2006 , 43, S35-43		11
487	General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. 2006 , 43, 89-95		48
486	Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. 2006 , 43, 107-17		31
485	Acute myeloid leukaemia. 2006 , 368, 1894-907		960
484	Adult acute myeloid leukemia. 2006 , 81, 247-60		90
483	Long-Term Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation in First Chronic Phase of Chronic Myeloid Leukemia. 2006 , 1, 123-129		
482	The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective. 2006 , 19, 637-53		14
481	Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. 2006 , 12, 172-83		119
480	Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. 2006 , 12, 217-25		42
479	Altered functional status of the hypothalamic dopaminergic tone in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a pilot study. 2006 , 12, 566-72		6
478	Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. 2006 , 12, 1326-34		88
477	Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect. 2006 , 42, 1601-11		13
476	Harnessing the Potential of Graft-vs-Tumor. 2006 , 235-261		
475	Historical perspective. 3-20		
474	[Fungal infection following reduced-intensity stem cell transplantation (RIST)]. 2006 , 47, 143-53		
473	Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. 2006 , 82, 913-9		45

472	Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation. 2006 , 18, 107-14		24
471	Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies. 2006 , 20, 496-503		2
470	Rapid progression of metastatic osteosarcoma after initiation of a reduced-intensity conditioning regimen with immunosuppressive fludarabine. 2006 , 10, 822-5		2
469	Nonmyeloablative Hematopoietic Cell Transplantation. 2006 , 938, 328-339		55
468	Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. 2006 , 133, 305-14		94
467	Current status of haploidentical stem cell transplantation. 2006 , 135, 423-37		55
466	Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). <i>Bone Marrow Transplantation</i> , 2006 , 37, 339-44	4.4	73
465	Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect. <i>Bone Marrow Transplantation</i> , 2006 , 37, 455-61	4.4	14
464	Increased intensity of acute graft-versus-host disease after reduced-intensity bone marrow transplantation compared to conventional transplantation from an HLA-matched sibling in children. <i>Bone Marrow Transplantation</i> , 2006 , 37, 601-5	4.4	4
463	Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and non-myeloablative stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2006 , 37, 837-43	4.4	35
462	Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. <i>Bone Marrow Transplantation</i> , 2006 , 37, 923-8	4.4	19
461	Skin cancer after nonmyeloablative hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2006 , 37, 1103-8	4.4	16
460	Myeloablative conditioning for hematopoietic stem-cell transplantation in patients with non-malignant diseases. <i>Bone Marrow Transplantation</i> , 2006 , 38, 321-2	4.4	2
459	Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?. <i>Bone Marrow Transplantation</i> , 2006 , 38, 359-64	4.4	7
458	Nonmyeloablative stem cell transplantation for nonmalignant diseases in children with severe organ dysfunction. <i>Bone Marrow Transplantation</i> , 2006 , 38, 665-9	4.4	24
457	Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. 2006 , 20, 128-35		202
456	Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. 2006 , 20, 322-8		257
455	Optimization of allogeneic transplant conditioning: not the time for dogma. 2006 , 20, 1701-5		41

454	Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct. 2006 , 20, 1673-82	33
453	Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. 2006 , 20, 1661-72	105
452	Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. 2006 , 20, 1690-700	135
451	Shared biology of GVHD and GVT effects: potential methods of separation. 2006 , 57, 225-44	60
450	Granulocyte colony-stimulating factor mobilizes more dendritic cell subsets than granulocyte-macrophage colony-stimulating factor with no polarization of dendritic cell subsets in normal donors. 2006 , 24, 1789-97	17
449	Successful reduced-intensity hematopoietic stem cell transplantation in myelodysplastic syndrome with severe coronary artery disease. 2006 , 83, 156-8	1
448	Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen. 2006 , 77, 341-4	2
447	A SYBR green-based real-time PCR method for detection of haemopoietic chimerism in allogeneic haemopoietic stem cell transplant recipients. 2006 , 77, 425-31	20
446	Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells. 2006 , 34, 475-85	10
445	Overcoming T cell-mediated rejection of bone marrow allografts by T-regulatory cells: synergism with veto cells and rapamycin. 2006 , 34, 802-8	26
444	Role of indirect allo- and autoreactivity in anti-tumor responses induced by recipient leukocyte infusions (RLI) in mixed chimeras prepared with nonmyeloablative conditioning. 2006 , 120, 33-44	17
443	Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors. 2006 , 11, 171-7	2
442	Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. 2006 , 11, 21-30	45
441	Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. 2006 , 24, 4150-7	88
440	Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. 2006 , 17, 1134-40	72
439	Results of genotypical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. 2006 , 24, 3959-66	40
438	Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. 2006 , 13, 26-41	57
437	Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience. 2006 , 36, 46-9	14

436	Reduced-intensity regimens in allogeneic hematopoietic stem cell transplantation for hemoglobinopathies. 2006 , 2006, 398-401		11
435	Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. 2007 , 25, 690-7		171
434	Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. 2007 , 178, 6242-51		112
433	Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. 2007 , 4, 404-14		31
432	Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. <i>Blood</i> , 2007 , 109, 3588-94	2.2	152
431	Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. <i>Blood</i> , 2007 , 109, 4686-92	2.2	127
430	Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. <i>Blood</i> , 2007 , 110, 3456-62	2.2	45
429	Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). <i>Blood</i> , 2007 , 109, 1395-400	2.2	209
428	Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. <i>Blood</i> , 2007 , 110, 4614-7 ^{2.2}		84
427	The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: a report from the Italian pediatric group. 2007 , 92, 1381-8		60
426	Reduced intensity transplantation for metastatic renal cell cancer with 2-year follow-up. 2007 , 30, 562-6		8
425	Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease. 2007 , 29, 1-6		17
424	Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. 2007 , 12, 193-7		8
423	Human thymus regeneration and T cell reconstitution. 2007 , 19, 280-8		27
422	Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program. 2007 , 13, 90-9		51
421	Allogeneic stem cell transplantation with T cell-depleted grafts for lymphoproliferative malignancies. 2007 , 13, 107-15		14
420	Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. 2007 , 13, 454-62		100
419	Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy. 2007 , 13, 790-805		10

418	Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. 2007 , 13, 844-52	59
417	Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. 2007 , 13, 932-41	26
416	Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation. 2007 , 13, 1022-30	9
415	Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. 2007 , 13, 1041-8	19
414	Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival. 2007 , 13, 1073-82	122
413	Allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome (MDS). 2007 , 33, S6-S10	1
412	Acute Myelogenous Leukemia. 2007 ,	
411	Immunotherapy by allogeneic stem cell transplantation. 2007 , 97, 25-60	26
410	Immunobiology of allogeneic hematopoietic stem cell transplantation. 2007 , 25, 139-70	390
409	Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning. 2007 , 22, 227-34	5
408	Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. 2007 , 82, 873-80	13
407	Progress in the treatment of acute myeloid leukemia. 2007 , 110, 1900-10	68
406	Allogeneic transplantation for myelodysplastic syndrome (MDS). 2007 , 21, 61-71	14
405	Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation. 2007 , 67, 544-51	11
404	Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. <i>Bone Marrow Transplantation</i> , 2007 , 39, 383-8	4.4 17
403	Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. <i>Bone Marrow Transplantation</i> , 2007 , 40, 19-27	4.4 27
402	Outpatient allografting using non-myeloablative conditioning: the Mexican experience. <i>Bone Marrow Transplantation</i> , 2007 , 40, 119-23	4.4 18
401	Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning. <i>Bone Marrow Transplantation</i> , 2007 , 40, 137-43	4.4 13

400	Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study. <i>Bone Marrow Transplantation</i> , 2007 , 40, 535-9	4-4	21
399	Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2007 , 40, 843-50	4-4	38
398	HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. 2007 , 21, 129-35		43
397	Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia. 2007 , 21, 1357-62		20
396	Review article: Stem cell transplantation for the treatment of gastrointestinal diseases--current applications and future perspectives. 2007 , 26 Suppl 2, 77-89		8
395	Thymus repopulation after allogeneic reconstitution in hematological malignancies. 2007 , 35, 1891-905		9
394	Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation. 2007 , 85, 256-63		10
393	The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome. 2007 , 85, 446-55		6
392	Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. 2008 , 112, 1992-2001		199
391	Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor. 2008 , 83, 630-4		2
390	Clinical outcomes of late rather than early full-donor chimerism in patients with advanced lymphomas receiving nonmyeloablative allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2008 , 42, 329-35	4-4	4
389	Reduced-intensity conditioning in children: a reappraisal in 2008. <i>Bone Marrow Transplantation</i> , 2008 , 41 Suppl 2, S18-22	4-4	14
388	Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. 2008 , 22, 258-64		53
387	Successful unmanipulated peripheral blood progenitor cell transplantation from an HLA haploidentical 2-locus-mismatched mother in a thalassemic patient with primary graft failure after transplantation of bone marrow and cord blood from unrelated donors. 2008 , 12, 232-4		6
386	Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Soci�t� Fran�aise de Greffe de Moelle et de Th�rapie Cellulaire. 2008 , 36, 535-44		47
385	Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation. 2008 , 36, 1750-9		10
384	Allogeneic bone marrow transplantation with reduced conditioning (RC-BMT). 2008 , 66, 73-82		1
383	Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation. 2008 , 66, 137-139		2

382	Post-transplant adoptive T-cell immunotherapy. 2008 , 21, 503-19	7
381	Graft failure after allogeneic hematopoietic cell transplantation. 2008 , 14, 165-70	133
380	ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients. 2008 , 14, 409-17	22
379	Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. 2008 , 14, 664-71	20
378	Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. 2008 , 14, 1298-304	18
377	In stem cell transplantation, by limiting the morbidity of graft-versus-host disease tolerance to myeloablative conditioning is improved. 2008 , 14, 709-18	1
376	Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies. 2008 , 55, 71-96, x	6
375	Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico. 2008 , 25, 39-47	5
374	Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. 2008 , 26, 577-84	173
373	Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. 2008 , 26, 455-62	253
372	The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. <i>Blood</i> , 2008 , 112, 3543-3553	306
371	Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant. 2008 , 6, 1017-25	12
370	Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose?. 2008 , 15, 555-60	32
369	Allogeneic bone marrow transplantation for severe aplastic anemia patients with risk factors for poor prognosis: is fludarabine a requirement?. 2008 , 30,	
368	Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. 2009 , 94, 1101-8	79
367	Relationship between tumor-infiltrating T lymphocytes and clinical response after reduced-intensity allogeneic hematopoietic stem cell transplantation for advanced renal cell carcinoma: a single center prospective study. 2009 , 39, 807-12	4
366	Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. 2009 , 27, 426-32	136
365	Chronic myeloid leukemia. 2009 , 35-41	

364	Multiple myeloma. 2009 , 81-96		
363	Primary immunodeficiency diseases. 2009 , 153-164		
362	Transplants from unrelated or mismatched family donors. 2009 , 293-301		
361	Management of the older patient. 2009 , 303-312		
360	Multiple organ failure and intensive care. 2009 , 457-465		1
359	Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. 2009 , 27, 4570-7		211
358	Early establishment of hematopoietic chimerism following allogeneic peripheral blood stem cell transplantation in comparison with allogeneic bone marrow transplantation. 1999 , 62, 265-70		8
357	Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model. 2009 , 37, 143-50		8
356	Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen. 2009 , 14, 197-201		1
355	A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients. 2009 , 63, 391-401		18
354	The allogeneic graft-versus-cancer effect. 2009 , 147, 614-33		117
353	Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors. <i>Bone Marrow Transplantation</i> , 2009 , 43, 327-33	4.4	14
352	Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. <i>Bone Marrow Transplantation</i> , 2009 , 43, 709-15	4.4	28
351	Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT. <i>Bone Marrow Transplantation</i> , 2009 , 43, 969-70	4.4	8
350	Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. <i>Bone Marrow Transplantation</i> , 2009 , 44, 13-7	4.4	17
349	Management of relapse after allo-SCT for AML and the role of second transplantation. <i>Bone Marrow Transplantation</i> , 2009 , 44, 769-77	4.4	51
348	Rapid full engraftment and successful immune reconstitution after allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in Omenn syndrome. 2009 , 13, 760-5		3
347	Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. 2009 , 15, 109-17		86

346	Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. 2009 , 15, 195-204	100
345	Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. 2009 , 15, 326-35	24
344	Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. 2009 , 15, 367-9	548
343	Allografting older patients--myths and realities. 2009 , 15, 146-8	4
342	Incidence and risk factors of early bacterial infections after unrelated cord blood transplantation. 2009 , 15, 439-46	34
341	What is the role for donor natural killer cells after nonmyeloablative conditioning?. 2009 , 15, 580-8	50
340	Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation. 2009 , 15, 679-85	6
339	Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. 2009 , 15, 694-703	63
338	Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. 2009 , 15, 919-29	33
337	[New modalities in hematopoietic stem cell transplant]. 2009 , 132, 391-3	
336	Principles and overview of allogeneic hematopoietic stem cell transplantation. 2009 , 144, 1-21	14
335	Defining the intensity of conditioning regimens: working definitions. 2009 , 15, 1628-33	1078
334	Aging, acute myelogenous leukemia, and allogeneic transplantation: do they belong in the same sentence?. 2009 , 9, 289-97	5
333	Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. 2009 , 9 Suppl 3, S261-5	10
332	An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. 2009 , 2009, 704928	12
331	Blood and Bone Marrow Transplantation for Acute Myeloid Leukemia. 2009 , 3, E11-E21	2
330	Stem cell transplants for patients with relapsed/refractory leukaemia. 2009 , 16, 444-52	7
329	Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Blood</i> , 2009 , 114, 5444-53	2.2 137

328	Reduced-intensity conditioning regimens before unrelated cord blood transplantation in adults with acute leukaemia and other haematological malignancies. 2009 , 21 Suppl 1, S31-4	41
327	Allogeneic transplantation for lymphoma: long-term outcome. 2010 , 17, 522-30	8
326	Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. 2010 , 95, 989-95	56
325	[Allogeneic cord blood transplantation for adults: current results and future development]. 2010 , 97, 137-48	
324	Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. 2010 , 89, 1045-52	7
323	Cost and effectiveness of reduced-intensity and conventional allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. 2010 , 18, 1565-9	7
322	Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation. 2010 , 91, 310-21	
321	Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype. 2010 , 91, 436-45	14
320	Reduced-intensity conditioning with Fludarabine, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. 2010 , 38, 1241-50	33
319	Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. 2010 , 148, 323-31	52
318	The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. 2010 , 24, 1852-8	49
317	Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. <i>Bone Marrow Transplantation</i> , 2010 , 45, 429-36	4.4 51
316	Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. <i>Bone Marrow Transplantation</i> , 2010 , 45, 633-9	4.4 38
315	Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. 2010 , 10, 213-21	192
314	Increased risk of bacterial infection after engraftment in patients treated with allogeneic bone marrow transplantation following reduced-intensity conditioning regimen. 2010 , 12, 412-20	11
313	Hematopoietic cell transplantation in older adults. 260-273	4
312	Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide. 2010 , 45, 102-8	8
311	Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. 2010 , 3, 301-14	6

310	Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. 2010 , 28, 1878-87	385
309	Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia. <i>Bone Marrow Transplantation</i> , 2010 , 45, 1300-8	4.4 12
308	Suicide gene therapy for graft-versus-host disease. 2010 , 2, 521-37	4
307	Bone marrow transplantation for primary immunodeficiency diseases. 2010 , 57, 207-37	27
306	Reduced intensity conditioning for hematopoietic stem cell transplantation: has it achieved all it set out to?. 2010 , 12, 440-54	4
305	Reduced intensity transplantation for primary immunodeficiency disorders. 2010 , 30, 103-24	13
304	Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. 2010 , 70, 691-732	68
303	Non-myeloablative umbilical cord blood transplantation. 2010 , 23, 231-6	1
302	Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency. 2010 , 16, 818-23	29
301	NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. 2010 , 16, 1037-69	36
300	Allogeneic hematopoietic cell transplantation: the state of the art. 2010 , 3, 285-99	116
299	Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. 2011 , 11 Suppl 1, S96-100	3
298	Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. 2011 , 25, 1025-48, vi	8
297	Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. 2011 , 24, 369-79	41
296	Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients. 2011 , 17, 841-51	27
295	The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection. 2011 , 17, 620-31	18
294	Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. 2011 , 17, 1196-204	51
293	National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. 2011 , 17, 443-54	35

292	Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. 2011 , 17, 1327-34		47
291	Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. 2011 , 17, 1688-97		106
290	Reduced-intensity allogeneic hematopoietic transplantation should be considered a standard of care for older patients with acute myeloid leukemia. 2011 , 17, 1723-4		8
289	Transplantation of CD6-depleted peripheral blood stem cells after DLA-haploidentical bone marrow transplantation contributes to engraftment and tolerance in a preclinical model of stem cell transplantation. 2011 , 144, 27-35		1
288	[Allogeneic hematopoietic stem cell transplantations]. 2011 , 18, 235-45		2
287	Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning. 2011 , 44, 205-10		18
286	Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission. 2011 , 17, 401-11		66
285	Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. 2011 , 58, 406-14		3
284	Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia. 2011 , 23, 197-202		31
283	Successful nonmyeloablative allogeneic stem cell transplantation for therapy-related acute myelogenous leukemia in a patient with preexisting visceral fungal infection. 2011 , 33, 62-4		0
282	Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. <i>Blood</i> , 2011 , 117, 6721-7	2.2	97
281	Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. 2011 , 25, 932-8		56
280	TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions. <i>Bone Marrow Transplantation</i> , 2011 , 46, 475-84	4.4	55
279	Three decades of transplantation for chronic myeloid leukemia: what have we learned?. <i>Blood</i> , 2011 , 117, 755-63	2.2	80
278	Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant. 2011 , 94, 266-278		2
277	[Allogeneic hematopoietic stem cell transplantation in elderly]. 2011 , 98, 915-25		3
276	A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies. 2011 , 22, 1865-71		8
275	Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning. <i>Leukemia and Lymphoma</i> , 2011 , 52, 321-4	1.9	1

274	Overcoming the age barrier in hematopoietic stem cell transplantation: progress, but still a long way to go. 2011 , 306, 1918-20		7
273	Optimizing management of invasive mould diseases. 2011 , 66 Suppl 1, i45-53		32
272	The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients. 2011 , 2011, 974658		3
271	Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective. 2011 , 34, 710-5		5
270	Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. 2011 , 29, 1342-8		157
269	Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. 2011 , 29, 566-72		21
268	Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. <i>Bone Marrow Transplantation</i> , 2012 , 47, 706-15	4-4	38
267	Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. <i>Bone Marrow Transplantation</i> , 2012 , 47, 203-11	4-4	212
266	Survival for older patients with acute myeloid leukemia: a population-based study. 2012 , 97, 1916-24		270
265	Hematopoietic stem cell and natural killer cell transplantation. 527-548		
264	Chronic myelogenous leukemia. 2012 , 10, 64-110		13
263	Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. 2012 , 89, 214-9		24
262	Is graft-versus-leukemia more effective using reduced-intensity conditioning compared with myeloablative conditioning?. 2012 , 18, 1615-7		1
261	Comparison of pulmonary complications after nonmyeloablative and conventional allogeneic hematopoietic cell transplant. 2012 , 18, 1827-34		15
260	Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies. 2012 , 8, 255-66; quiz 267		47
259	Mesenchymal stromal cells: a new tool against graft-versus-host disease?. 2012 , 18, 822-40		81
258	Estimating the treatment effect from non-randomized studies: The example of reduced intensity conditioning allogeneic stem cell transplantation in hematological diseases. 2012 , 12, 10		6
257	Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. 2012 , 13, 1035-44		190

256 Myelodysplasia. **2012**, 363-374

255	Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I). 2012 , 8, 1254-64		8
254	Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. 2012 , 18, 1422-9		46
253	Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. <i>Blood</i> , 2012 , 119, 1599-606	2.2	191
252	Targeting natural killer cells and natural killer T cells in cancer. 2012 , 12, 239-52		562
251	Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. <i>Blood</i> , 2012 , 119, 5632-9	2.2	54
250	Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. 2012 , 91, 931-9		56
249	A comparison of oral mucositis in allogeneic hematopoietic stem cell transplantation between conventional and reduced-intensity regimens. 2012 , 20, 933-9		15
248	Frequency and prognostic value of D alloantibodies after D-mismatched allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning. 2012 , 52, 1348-53		8
247	Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies. 2013 , 97, 581-98		18
246	Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. 2013 , 31, 3259-71		101
245	Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience. 2013 , 49, 590-9		8
244	Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia. 2013 , 26, 297-300		19
243	Allogeneic hematopoietic stem cell transplantation for multiple myeloma: what place, if any?. 2013 , 8, 284-90		7
242	Gene therapy on the move. 2013 , 5, 1642-61		187
241	Clinical guide to ABO-incompatible allogeneic stem cell transplantation. 2013 , 19, 1152-8		93
240	A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiopeta and rabbit antithymocyte globulin. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1713-8	1.9	1
239	The quest for the optimal conditioning regimen: some answers, more questions. 2013 , 19, 1275-6		2

238	A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. 2013 , 19, 1453-8		15
237	Allogeneic hematopoietic cell transplantation in septuagenarians. 2013 , 19, 1276-8		
236	Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: the cost of freedom. 2013 , 19, 860-6		12
235	Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. 2013 , 19, 1087-93		11
234	Graft failure in the modern era of allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2013 , 48, 537-43	4.4	163
233	Special Care of Blood and Marrow Stem Transplant Patients. 2013 , 1321-1345		
232	Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS. <i>Bone Marrow Transplantation</i> , 2013 , 48, 1296-301 ^{4.4}		23
231	Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. 2013 , 119, 602-11		55
230	The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2013 , 48, 1409-14	4.4	52
229	The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2013 , 48, 238-42	4.4	21
228	Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation. 2013 , 18, 173-92		6
227	Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). <i>Blood</i> , 2013 , 122, 1974-82	2.2	69
226	Reduced Intensity Conditioning in Paediatric Haematopoietic Cell Transplantation. 2013 , 116-134		1
225	Myelodysplastic syndromes: clinical practice guidelines in oncology. 2013 , 11, 838-74		72
224	Non-myeloablative allogeneic hematopoietic transplantation for patients with hematologic malignancies: 9-year single-centre experience. 2014 , 21, e434-40		1
223	Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014 , 49, 389-96	4.4	82
222	Feasibility of an outpatient HLA haploidentical stem cell transplantation program in children using a reduced-intensity conditioning regimen and CD3-CD19 depletion. 2014 , 19, 10-7		4
221	Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. 2014 , 99, 1486-91		23

220	Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen. <i>Bone Marrow Transplantation</i> , 2014 , 49, 1492-7	4.4	3
219	Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients. 2014 , 92, 137-46		10
218	Acute myeloid leukemia: 2014 update on risk-stratification and management. 2014 , 89, 1063-81		104
217	Immunotherapy following relapse of acute leukaemia after T-cell-replete allogeneic peripheral blood progenitor cell transplantation: importance of new onset chronic graft-versus-host disease. 2014 , 36, 197-204		4
216	Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. <i>Blood</i> , 2014 , 124, 344-53	2.2	284
215	Recent advances in transplantation for primary immune deficiency diseases: a comprehensive review. 2014 , 46, 131-44		14
214	Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. 2014 , 61, 712-6		10
213	The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML. <i>Bone Marrow Transplantation</i> , 2014 , 49, 1498-504	4.4	10
212	Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. 2014 , 20, 1777-84		40
211	Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. 2014 , 22, 2133-40		21
210	Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience. 2014 , 20, 1217-23		28
209	The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation. 2014 , 20, 1211-6		38
208	Peripheral blood stem cells or bone marrow as the graft source for allogeneic hematopoietic cell transplantation?. 2014 , 9, 91-99		1
207	Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome. 2014 , 20, 1418-25		33
206	Similar survival for patients undergoing reduced-intensity total body irradiation (TBI) versus myeloablative TBI as conditioning for allogeneic transplant in acute leukemia. 2014 , 89, 360-9		6
205	Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood. 2014 , 99, 370-7		41
204	Treatment of chronic graft-versus-host disease with bortezomib. <i>Blood</i> , 2014 , 124, 1677-88	2.2	60
203	The biology of graft-versus-host disease: experimental systems instructing clinical practice. <i>Blood</i> , 2014 , 124, 354-62	2.2	125

202	The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. 2015 , 100, 683-9		29
201	Reduced-toxicity myeloablative conditioning consisting of 8-Gy total body irradiation, cyclophosphamide and fludarabine for pediatric hematological malignancies. 2014 , 4, 6942		4
200	Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. 2015 , 100, 269-74		22
199	Immunotherapy in acute myeloid leukemia. 2015 , 121, 2689-704		28
198	Reduced-intensity conditioned allogeneic SCT in adults with AML. <i>Bone Marrow Transplantation</i> , 2015 , 50, 759-69	4.4	28
197	Hematopoiesis in Regenerative Medicine. 2015 , 375-401		
196	Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases. <i>Bone Marrow Transplantation</i> , 2015 , 50, 324-33	4.4	4
195	MicroRNAs as biomarkers for graft-versus-host disease following allogeneic stem cell transplantation. 2015 , 94, 1081-92		17
194	Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. 2015 , 94, 1033-41		6
193	Busulfan-based conditioning regimens: not all partners are equal. 2015 , 16, 1448-1449		3
192	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. 2015 , 33, 4167-75		111
191	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. 2015 , 16, 1525-1536		103
190	Is peripheral blood or bone marrow a better source of stem cells for transplantation in cases of HLA-matched unrelated donors? A meta-analysis. 2015 , 96, 20-33		9
189	Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis. 2015 , 15 Suppl, S34-42		
188	Aging and transplanting graciously. 2015 , 2, e398-9		1
187	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective. 2015 , 101, 243-54		18
186	Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. 2015 , 121, 1048-55		56
185	Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML. <i>Bone Marrow Transplantation</i> , 2015 , 50, 74-81	4.4	21

- 184 Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments. **2016**, 7, 470 58
- 183 T Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical Outcome. **2016**, 17, 11
- 182 A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. **2016**, 174, 700-10 36
- 181 . **2016**, 103 Suppl 1, S164-S174
- 180 Disminuci3n de mortalidad en hemopat3as malignas con un nuevo m3todo de acondicionamiento para trasplante alog3nico mieloablativo. **2016**, 15, 16-21
- 179 Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. **2016**, 22, 1808-1815¹⁸
- 178 A History of Allogeneic and Autologous Hematopoietic Cell Transplantation. **2016**, 1-11
- 177 Reduced-intensity Allogeneic Transplantation Regimens. **2016**, 232-246
- 176 The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation. **2016**, 349-365
- 175 Hematopoietic Cell Transplantation for Aplastic Anemia. **2016**, 517-540 1
- 174 Hematopoietic Cell Transplantation for Renal Cell Carcinoma and Other Solid Tumors. **2016**, 748-761
- 173 Blood Group Incompatibilities and Hemolytic Complications of Hematopoietic Cell Transplantation. **2016**, 955-962 1
- 172 Matched unrelated donor transplants-State of the art in the 21st century. **2016**, 53, 221-229 6
- 171 Acute myeloid leukemia: 2016 Update on risk-stratification and management. **2016**, 91, 824-46 43
- 170 Allogeneic Stem Cell Transplantation: A Historical and Scientific Overview. **2016**, 76, 6445-6451 98
- 169 Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. **2016**, 6, e449 50
- 168 Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. **2016**, 22, 1431-1439 18
- 167 The hematopoietic system in the context of regenerative medicine. **2016**, 99, 44-61 37

166	Short- and long-term outcomes of adult allogeneic hematopoietic stem cell transplant patients admitted to the intensive care unit in the peritransplant period. <i>Leukemia and Lymphoma</i> , 2017 , 58, 382-390	1.0	15
165	Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. 2017 , 123, 2025-2034		32
164	Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation. 2017 , 92, 388-396		17
163	Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. 2017 , 35, 1154-1161		354
162	Hematopoietic Cell Transplantation. 2017 , 1-13		1
161	First French experiences of total body irradiations using helical TomoTherapy. 2017 , 21, 365-372		10
160	Haematopoietic Stem Cell Transplantation. 2017 , 466-476		
159	Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. 2017 , 102, 224-234		61
158	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. <i>Bone Marrow Transplantation</i> , 2017 , 52, 620-621	4.4	16
157	Bone Marrow Graft-Versus-Host Disease in Major Histocompatibility Complex-Matched Murine Reduced-Intensity Allogeneic Hemopoietic Cell Transplantation. 2017 , 101, 2695-2704		
156	Infections in Hematopoietic Stem Cell Transplant Recipients. 2017 , 739-745.e3		
155	Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT. 2017 , 176, 431-439		20
154	Autologous Hematopoietic Cell Transplants for Plasma Cell Myeloma: One, Two, or None?. 445-457		
153	Allogeneic Hematopoietic Cell Transplants for Plasma Cell Myeloma. 468-476		
152	Transfusion in Transplantation. 2017 ,		
151	Allogeneic bone marrow transplant in the absence of cytoreductive conditioning rescues mice with <i>Ethalassemia major</i> . <i>Blood Advances</i> , 2017 , 1, 2421-2432	7.8	5
150	Donor Selection for Allogenic Hemopoietic Stem Cell Transplantation: Clinical and Ethical Considerations. 2017 , 2017, 5250790		14
149	Conditioning Regimens: Do They Really Matter?. 247-257		

148	Reduced Intensity for Myelodysplastic Syndrome: Worth the Gamble?. 2017 , 35, 2106-2108		4
147	Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. 2018 , 97, 1115-1153		55
146	Mechanical Ventilation in Critically Ill Cancer Patients. 2018 ,		
145	Insights into cell-free therapeutic approach: Role of stem cell "soup-ernatant". 2018 , 65, 104-118		16
144	Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. 2018 , 24, 1232-1236		36
143	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018 , 2, 2922-2936	7.8	17
142	Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies. 2018 , 97, 1975-1985		3
141	Myelodysplastic Syndromes. 2018 ,		
140	Allogeneic Stem Cell Transplantation for MDS. 2018 , 141-157		
139	End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center. <i>Bone Marrow Transplantation</i> , 2019 , 54, 700-706	4.4	4
138	Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis. <i>Bone Marrow Transplantation</i> , 2019 , 54, 531-539	4.4	13
137	Conditioning intensity and antilymphocyte globulin: towards personalized transplant strategies?. 2019 , 104, 1101-1102		1
136	History and Current Status of Hematopoietic Cell Transplantation. 2019 , 1-18		
135	The Role of Radiation Therapy in Hematopoietic Stem Cell Transplantation. 2019 , 59-72		0
134	Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. 2019 , 94, 1344-1352		4
133	Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience. 2019 , 21, e13187		28
132	Principles of Hematopoietic Stem Cell Transplantation. 2019 , 153-163		0
131	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. 2019 , 25, 1975-1983		32

130	National survey on total-body irradiation prior to reduced-intensity stem cell transplantation in Japan: The Japanese Radiation Oncology Study Group. 2019 , 60, 579-585		2
129	The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Diseases Is Influenced by HLA Match, Year of Transplantation, and Immunized Female Donor. 2019 , 103, 1247-1252		1
128	Efficacy of three consecutive therapeutic plasma exchanges in major ABO-incompatible hematopoietic stem cell transplantation. 2019 , 34, 367-372		2
127	Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis. 2019 , 25, 728-733		16
126	Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over. 2019 , 125, 1499-1506		12
125	Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study. <i>Bone Marrow Transplantation</i> , 2019 , 54, 894-902	4.4	7
124	Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI). <i>Bone Marrow Transplantation</i> , 2020 , 55, 562-569	4.4	5
123	Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2020 , 55, 729-739	4.4	1
122	Hematopoietic Stem Cell Transplantation. 2020 , 461-469.e3		1
121	The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. 2020 , 188, 129-146		29
120	Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible. 2020 , 10, 1746		1
119	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020 , 4, 3180-3190	7.8	4
118	Role of Stem-Cell Transplantation in Leukemia Treatment. 2020 , 13, 67-77		3
117	Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1955-1965	4.4	2
116	CAR T cells: continuation in a revolution of immunotherapy. 2020 , 21, e168-e178		86
115	Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. 2021 , 127, 1598-1605		3
114	Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care. 2021 , 113, 712-722		1
113	Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1842-1849	4.4	0

112	Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation. 2021 , 11, 80	2
111	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?. 2021 , 12, 659595	6
110	Outcome of allogeneic hematopoietic stem cell transplant recipients admitted to the intensive care unit with a focus on haploidentical graft and sequential conditioning regimen: results of a retrospective study. 2021 , 100, 2787-2797	
109	History of Bone Marrow Transplantation. <i>Organ and Tissue Transplantation</i> , 2021 , 3-26	0
108	Reduced-intensity and nonmyeloablative conditioning regimens. 2009 , 144, 209-32	2
107	Allogeneic hematopoietic stem cell transplantation for cytokine refractory renal cell carcinoma. 2003 , 116, 213-26	10
106	Development of allogeneic hematopoietic stem cell transplantation (HSCT). 2002 , 110, 1-37	2
105	Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer. 2002 , 110, 101-12	14
104	Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice. 2002 , 110, 113-36	6
103	Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy. 2002 , 110, 137-47	4
102	Outpatient allografting in hematologic malignancies and nonmalignant disorders--applying lessons learned in the canine model to humans. 2002 , 110, 149-75	7
101	Adoptive immunotherapy using donor leukocyte infusions to treat relapsed hematologic malignancies after allogeneic bone marrow transplantation. 1999 , 101, 233-66	2
100	Non Myeloablative Mini Transplants 1999, 97-108	32
99	Guidelines for Clinical Management of CLL. 2004 , 219-240	1
98	Graft-vs-Host Disease. 2000 , 229-248	1
97	Nonmyeloablative Transplantation. 2004 , 469-484	1
96	Concepts and Controversies in the Use of Novel Preparative Regimens for Allogeneic Stem Cell Transplantation. 2010 , 441-458	1
95	Conditioning. 2019 , 99-107	7

94	Non-myeloablative stem cell transplantation for congenital immunodeficiencies. 2002 , 159, 134-42	14
93	Induction of Mixed Chimerism in Patients After Non-Myeloablative Stem Cell Transplantation (SCT) for High Risk Haematological Malignancies. <i>Hamatologie Und Bluttransfusion</i> , 2003 , 514-519	1
92	Non-Hodgkin's Lymphoma. 2008 , 2371-2404	3
91	Hematopoietic stem cell transplantation. 599-624	2
90	Allogeneic bone marrow transplantation with reduced conditioning (RC-BMT). 2001 , 66, 73-82	16
89	Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation. 2001 , 66, 137-9	23
88	Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. 2000 , 111, 18-29	160
87	Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. 2000 , 111, 292-302	78
86	Non-myeloablative stem cell transplants. 2000 , 111, 6-17	86
85	Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. 2000 , 111, 797-800	7
84	Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. 1999 , 11, 87-95	60
83	Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. 1999 , 68, 480-4	341
82	Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy. 2000 , 69, 1358-63	20
81	Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer. 2000 , 69, 2043-8	27
80	Stem cell transplantation eliminates alloantibody in a highly sensitized patient. 2001 , 72, 1653-5	12
79	Nonmyeloablative stem cell transplants. 1999 , 6, 383-7	11
78	Minitransplants and cell-based therapies for malignant and nonmalignant disorders. 1999 , 4, 184-188	5
77	Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning. 2003 , 112, 795-808	67

76	Adoptive T cell therapy for cancer in the clinic. 2007 , 117, 1466-76		400
75	Non-myeloablative transplantation. 2002 , 392-421		35
74	New Developments in the Therapy of Acute Myelocytic Leukemia. 2000 , 2000, 69-89		2
73	Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors. 2003 , 2003, 372-397		9
72	Do different conditioning regimens really make a difference?. 2012 , 2012, 237-245		23
71	Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoablation for the Treatment of Malignant and Nonmalignant Hematologic Diseases. <i>Blood</i> , 1998 , 91, 756-763	2.2	23
70	Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 1998 , 92, 1910-1917	2.2	3
69	Engraftment Kinetics After Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation: Full Donor T-Cell Chimerism Precedes Alloimmune Responses. <i>Blood</i> , 1999 , 94, 3234-3241	2.2	13
68	Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. <i>Blood</i> , 2000 , 96, 1239-1246		5
67	How I treat older patients with AML. <i>Blood</i> , 2000 , 96, 1670-1673	2.2	2
66	In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. <i>Blood</i> , 2000 , 96, 2419-2425	2.2	6
65	Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. <i>Blood</i> , 2001 , 97, 631-637	2.2	5
64	An anti-human thymocyte globulin-based reduced-intensity conditioning regimen is associated with a higher quality of life and lower organ toxicity without affecting lymphocyte reconstitution. 2013 , 8, e73755		3
63	Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. 2018 , 9, 11451-11464		32
62	Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC. 2018 , 9, 36603-36612		5
61	History of hematopoietic cell transplantation: challenges and progress. 2020 , 105, 2716-2729		12
60	Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation. 2009 , 24, 287-98		6
59	Hematopoietic Cell Transplantation: The First 50 Years and a Glimpse of the Future. 2000 , 3-10		

- 58 Stem Cell Transplantation for Chronic Myeloid Leukemia. **2000**, 83-93
- 57 GVL Effects in Human Marrow Stem-Cell Transplants. **2000**,
- 56 New Developments in the Therapy of Acute Myelocytic Leukemia. **2000**, 2000, 69-89 2
- 55 Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy. **2000**, 185-193
- 54 Nonmyeloablative Allogeneic Stem Cell Transplantation: Towards Improving Efficacy of Immunotherapy Instead of Myeloablative Chemoradiotherapy. **2000**, 112-117
- 53 Autograft Followed by Allograft Without Myeloablative Conditioning Regimen: A New Approach for Resistant Hematologic Neoplasia and Breast Cancer. **2000**, 211-216
- 52 Exploring the potential for graft vs. tumor response in a combine bone marrow and liver transplantation for large hepatocellular carcinoma. **2000**, 69, 2003-4
- 51 Dose Reduced Conditioning for Allogeneic Blood Stem Cell Transplantation from Sibling and Unrelated Donors in 51 Patients. *Hamatologie Und Bluttransfusion*, **2001**, 685-694
- 50 Shifting Towards Better Immunotherapy Rather Than More Intensive Chemoradiotherapy Using a Non-Myeloablative Approach in Patients with Leukemia. *Hamatologie Und Bluttransfusion*, **2001**, 674-677
- 49 Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. *Blood*, **2002**, 99, 2255-2258 2.2 0
- 48 Nonmyeloablative Allogeneic Transplantation. **2003**, 169-188
- 47 Hematopoietic Stem Cell Transplantation. **2003**, 3-9
- 46 Dose Reduced Conditioning for Allogeneic Blood Stem Cell Transplantation from Sibling and Unrelated Donors in 51 Patients. **2003**, 59-73
- 45 Current Role of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation in Patients with AML. *Hamatologie Und Bluttransfusion*, **2003**, 473-478
- 44 Adoptive Immunotherapy in Chimeras. **2003**, 3-10
- 43 Nonmyeloablative Conditioning Regimen in Patients with High Risk Acute Myeloid Leukemia: Unrelated and Sibling Allogeneic Hematopoietic Stem Cell Transplantation. *Hamatologie Und Bluttransfusion*, **2003**, 508-513
- 42 Non-Myeloablative Stem Cell Transplantation for Acute Myelogenous Leukemia. *Hamatologie Und Bluttransfusion*, **2003**, 483-484
- 41 Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia. **2004**, 25-45

- 40 Maligne Lymphome. **2004**, 1711-1774
- 39 Role of Cytokines in the Management of Chronic Lymphocytic Leukemia. **2004**, 311-332
- 38 Allogeneic Hematopoietic Blood-Cell Transplantation As Immunotherapy for Metastatic Renal Cell Carcinoma. **2004**, 279-293
- 37 Nonmyeloablative Stem Cell Transplantation in the Treatment of Hematologic Malignancies. **2006**, 351-360
- 36 Morphological Variation of Ten Ipomoea Species of Bangladesh. *Pakistan Journal of Biological Sciences*, **2006**, 9, 1714-1719 0.8 1
- 35 Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment. *Archives of Pathology and Laboratory Medicine*, **2006**, 130, 1479-88 5 1
- 34 Stem Cell Transplantation for AML. **2007**, 313-327
- 33 Haploidentical Stem Cell Transplantation. **2008**, 289-317
- 32 Stem Cell Transplantation for Hemoglobinopathies. **2008**, 201-221
- 31 Hematopoietic Stem Cell Transplantation. **2008**, 501-512 1
- 30 Allogeneic Hematopoietic Cell Transplantation from an HLA-mismatched Family Donor: The Current Status and Future. *Journal of the Korean Medical Association*, **2009**, 52, 819 0.5
- 29 The Role of Allogeneic Bone Marrow Transplant in Cancer Treatment. **2010**, 229-239
- 28 Full Intensity and Reduced Intensity Allogeneic Transplantation in AML. **2010**, 11-27
- 27 Blood and Bone Marrow Transplantation for Acute Myeloid Leukemia. **2009**, 3, E14-E24
- 26 Retrospective Analysis of Reduced Intensity Conditioning Stem Cell Transplantation for Hematological Malignancies. *Yamaguchi Medical Journal*, **2010**, 59, 63-70 0
- 25 Infections in hematopoietic stem cell transplant recipients. **2010**, 821-828
- 24 Hematopoietic Stem-Cell Transplantation for Acute Myelogenous Leukemia. 148-160
- 23 Myelodysplastic Syndromes. 99-114

22	Non-Neoplastic Hematopathology of Bone Marrow Transplant and Infections. 537-557		
21	Harnessing Allogeneic Immunity for Anti-myeloma Response. 2013 , 111-129		
20	Haemopoietic Stem Cell Transplantation. 455-463		
19	Preparative Regimens. <i>Pediatric Oncology</i> , 2014 , 41-56	0.5	
18	The Development of Hematopoietic Cell Transplantation and its Application to Organ Transplantation and Autoimmune Diseases. 1999 , 1-5		
17	Conditioning Regimens. 1999 , 53-67		
16	Blood Marrow Transplantation. 2018 , 47-57		
15	Historical Overview of Pediatric HSCT. 2018 , 7-18		
14	Special Care of Blood and Marrow Hematopoietic Cell Transplant Recipient. 2018 , 1211-1245		
13	History of Bone Marrow Transplantation. <i>Organ and Tissue Transplantation</i> , 2020 , 1-24	0	
12	Hematopoietic Stem Cell Transplantation: Allogeneic Immunotherapy for Cancer. 2008 , 495-503		
11	Surgical Therapy for Atrial Fibrillation. 2008 , 225-232		
10	Allogeneic Transplantation for CML. 2007 , 115-131		
9	Antibody-drug conjugates targeting CD45 plus Janus kinase inhibitors effectively condition for allogeneic hematopoietic stem cell transplantation.		
8	Radioimmunotherapy of Acute Leukemia. 2022 , 433-447		
7	Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation.. <i>Leukemia and Lymphoma</i> , 2022 , 1-8	1.9	○
6	Impact of the MRD status in AML patients undergoing allogeneic stem cell transplantation in first vs second remission. <i>Blood Advances</i> ,	7.8	○
5	Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation. <i>Bone Marrow Transplantation</i> ,	4.4	○

4 Haematopoietic Cell Transplantation. **2022**, 531-542

3 Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. *Bone Marrow Transplantation*, 44 1

2 The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia. 0

1 Transplantation. **2023**, 599-674 0